Compare VAL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | ACAD |
|---|---|---|
| Founded | 1975 | 1993 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.4B |
| IPO Year | N/A | 2004 |
| Metric | VAL | ACAD |
|---|---|---|
| Price | $58.69 | $25.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 22 |
| Target Price | ★ $54.80 | $30.00 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 02-18-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | ★ 5.61 | 1.54 |
| Revenue | ★ $2,416,000,000.00 | $1,047,118,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | N/A | $11.79 |
| P/E Ratio | ★ $10.14 | $16.62 |
| Revenue Growth | 6.81 | ★ 12.69 |
| 52 Week Low | $27.15 | $13.40 |
| 52 Week High | $61.70 | $28.35 |
| Indicator | VAL | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 43.48 |
| Support Level | $55.95 | $25.25 |
| Resistance Level | $59.54 | $27.22 |
| Average True Range (ATR) | 2.03 | 0.94 |
| MACD | 0.61 | -0.16 |
| Stochastic Oscillator | 80.00 | 18.36 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.